FDA Approved Products

99 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Active:Lifecycle: LaunchClear all
ELIQUIS
apixaban
Launch
Bristol Myers Squibb
ORAL · SUSPENSION
deep vein thrombosis (DVT)which may lead to pulmonary embolism (PE)+11
2025
NDA
0/100
ELIQUIS SPRINKLE
apixaban
Launch
Bristol Myers Squibb
ORAL · FOR SUSPENSION
deep vein thrombosis (DVT)which may lead to pulmonary embolism (PE)+11
2025
NDA
0/100
ENBUMYST
bumetanide
Launch
NASAL · SPRAY
edema associated with congestive heart failurehepatic+3
2025
NDA
0/100
FORZINITY
elamipretide hydrochloride
Launch
Stealth BioTherapeutics
SUBCUTANEOUS · SOLUTION
muscle strength in adult
2025
NDA
0/100
HERNEXEOS
zongertinib
Launch
Boehringer Ingelheim
ORAL · TABLET
2025
SMNDA
0/100
HYRNUO
sevabertinib
Launch
Bayer
ORAL · TABLET
metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutationsdetected by an FDA-approved test+1
2025
SMNDA
0/100
IBTROZI
taletrectinib
Launch
ORAL · CAPSULE
Administration ()]metastatic ROS1 -positive non-small cell lung cancer (NSCLC)+1
2025
SMNDA
0/100
INLEXZO
gemcitabine intravesical
Launch
Johnson & Johnson
INTRAVESICAL · SYSTEM
2025
NDA
0/100
INLURIYO
imlunestrant
Launch
Eli Lilly and Company
ORAL · TABLET
2025
NDA
0/100
JASCAYD
nerandomilast
Launch
Boehringer Ingelheim
ORAL · TABLET
idiopathic pulmonary fibrosis (IPF) in adult patientsprogressive pulmonary fibrosis (PPF) in adult patients
2025
NDA
0/100
JAVADIN
clonidine hydrochloride oral
Launch
R-Pharm US
ORAL · SOLUTION
hypertension in adult patients to lower blood pressurehypertension
2025
NDA
0/100
KHINDIVI
hydrocortisone
Launch
ORAL · SOLUTION
2025
NDA
0/100
KOMZIFTI
ziftomenib
Launch
ORAL · CAPSULE
2025
SMNDA
0/100
KYGEVVI
doxecitine and doxribtimine
Launch
UCB Pharma
ORAL · FOR SOLUTION
thymidine kinase 2 deficiency (TK2d) in adultsbefore 12 years
2025
NDA
0/100
KYXATA
carboplatin
Launch
Viatris (2)
INTRAVENOUS · SOLUTION
for the initial treatment of advanced ovarian carcinoma
2025
NDA
0/100
LIVMARLI
maralixibat chloride
Launch
Mirum Pharmaceuticals
ORAL · TABLET
cholestatic pruritus in patients 3 months of ageolder with Alagille syndrome (ALGS)+2
2025
NDA
0/100
LYNKUET
elinzanetant
Launch
Bayer
ORAL · CAPSULE
moderate to severe vasomotor symptoms due to menopause
2025
NDA
0/100
MEZOFY
aripiprazole
Launch
ORAL · FILM
2025
SMNDA
0/100
MODEYSO
dordaviprone
Launch
Chimerix
ORAL · CAPSULE
older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
2025
NDA
0/100
MYQORZO
aficamten
Launch
Cytokinetics
ORAL · TABLET
symptoms
2025
NDA
0/100
NEREUS
tradipitant
Launch
Vanda Pharmaceuticals
ORAL · CAPSULE
2025
NDA
0/100
NUZOLVENCE
zoliflodacin
Launch
ORAL · FOR SUSPENSION
2025
NDA
0/100
ORLADEYO
berotralstat hydrochloride
Launch
BioCryst Pharmaceuticals
ORAL · PELLETS
2025
NDA
0/100
OTEZLA
apremilast
Launch
Amgen
ORAL · TABLET
2025
NDA
0/100